↓ Skip to main content

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

Overview of attention for article published in Breast Cancer Research, January 2020
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news
1 news outlet
twitter
4 X users
patent
1 patent

Citations

dimensions_citation
66 Dimensions

Readers on

mendeley
66 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
Published in
Breast Cancer Research, January 2020
DOI 10.1186/s13058-019-1243-8
Pubmed ID
Authors

Lori J. Goldstein, Raymond P. Perez, Denise Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato, Jenny C. Chang

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 66 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 10 15%
Student > Bachelor 10 15%
Researcher 10 15%
Student > Master 7 11%
Student > Doctoral Student 1 2%
Other 4 6%
Unknown 24 36%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 11 17%
Immunology and Microbiology 7 11%
Medicine and Dentistry 7 11%
Nursing and Health Professions 4 6%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Other 8 12%
Unknown 25 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 August 2021.
All research outputs
#2,544,525
of 25,387,668 outputs
Outputs from Breast Cancer Research
#252
of 2,054 outputs
Outputs of similar age
#60,101
of 473,273 outputs
Outputs of similar age from Breast Cancer Research
#6
of 34 outputs
Altmetric has tracked 25,387,668 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,054 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 473,273 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.